These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 16228054)

  • 21. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
    Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
    East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].
    Sáenz González MC; Núñez Mateos JC; Rodrigo Sánchez N; Martín Sánchez AM
    An Esp Pediatr; 1992 Apr; 36(4):293-7. PubMed ID: 1605414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 27. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seroresponse to the second measles vaccine dose at school entry in Qassim province, Saudi Arabia.
    Khalil MK; Nadrah HM; Al Yahia OA; ElGhazali G
    East Mediterr Health J; 2011 Mar; 17(3):191-5. PubMed ID: 21735958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study.
    Heijstek MW; van Gageldonk PG; Berbers GA; Wulffraat NM
    Ann Rheum Dis; 2012 Jun; 71(6):948-54. PubMed ID: 22172491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
    France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
    Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
    Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
    Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measles immunization in Saudi Arabia: the need for change.
    Khalil MK; Al-Mazrou YY; Al-Jeffri M; Al-Ghamdy YS
    East Mediterr Health J; 2001; 7(4-5):829-34. PubMed ID: 15332786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign.
    Kelly HA; Gidding HF; Karapanagiotidis T; Leydon JA; Riddell MA
    BMC Public Health; 2007 Jun; 7():99. PubMed ID: 17555601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
    Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
    J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.